These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37543205)

  • 1. Toward Best Practices for Economic Evaluations of Tumor-Agnostic Therapies: A Review of Current Barriers and Solutions.
    Weymann D; Pollard S; Lam H; Krebs E; Regier DA
    Value Health; 2023 Nov; 26(11):1608-1617. PubMed ID: 37543205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
    Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
    Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA).
    Paracha N; Hudson P; Mitchell S; Sutherland CS
    Pharmacoeconomics; 2022 Apr; 40(Suppl 1):69-89. PubMed ID: 34658008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
    Brettschneider C; Lühmann D; Raspe H
    GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allocating healthcare resources to genomic testing in Canada: latest evidence and current challenges.
    Weymann D; Dragojlovic N; Pollard S; Regier DA
    J Community Genet; 2022 Oct; 13(5):467-476. PubMed ID: 31273679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
    Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
    Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
    Ball G; Levine MAH; Thabane L; Tarride JE
    Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Over-, under- and misuse of pain treatment in Germany.
    Dietl M; Korczak D
    GMS Health Technol Assess; 2011 Apr; 7():Doc03. PubMed ID: 21522485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Challenges in Conducting Economic Evaluations for Rehabilitation Technologies.
    Chan BC
    Top Spinal Cord Inj Rehabil; 2023; 29(Suppl):44-52. PubMed ID: 38174139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges and Solutions for the Benefit Assessment of Tumor-Agnostic Therapies in Germany.
    Schiller J; Eckhardt H; Schmitter S; Alber VA; Rombey T
    Value Health; 2023 Jun; 26(6):854-864. PubMed ID: 36709043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the clinical effectiveness and cost-effectiveness of conservative interventions for tendinopathy? An overview of systematic reviews of clinical effectiveness and systematic review of economic evaluations.
    Long L; Briscoe S; Cooper C; Hyde C; Crathorne L
    Health Technol Assess; 2015 Jan; 19(8):1-134. PubMed ID: 25629427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telephone interventions for symptom management in adults with cancer.
    Ream E; Hughes AE; Cox A; Skarparis K; Richardson A; Pedersen VH; Wiseman T; Forbes A; Bryant A
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD007568. PubMed ID: 32483832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluations conducted by Canadian health technology assessment agencies: where do we stand?
    Tarride JE; McCarron CE; Lim M; Bowen JM; Blackhouse G; Hopkins R; O'Reilly D; Xie F; Goeree R
    Int J Technol Assess Health Care; 2008; 24(4):437-44. PubMed ID: 18828938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid antigen detection and molecular tests for group A streptococcal infections for acute sore throat: systematic reviews and economic evaluation.
    Fraser H; Gallacher D; Achana F; Court R; Taylor-Phillips S; Nduka C; Stinton C; Willans R; Gill P; Mistry H
    Health Technol Assess; 2020 Jun; 24(31):1-232. PubMed ID: 32605705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What do we know about managing Dupuytren's disease cost-effectively?
    Dritsaki M; Rivero-Arias O; Gray A; Ball C; Nanchahal J
    BMC Musculoskelet Disord; 2018 Jan; 19(1):34. PubMed ID: 29370792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.